跳至主要内容
临床试验/NCT01962324
NCT01962324已完成不适用

Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV

Umeå University2 个研究点 分布在 1 个国家目标入组 85 人开始时间: 2015年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
85
试验地点
2
主要终点
PSA progression free survival

研究概览

简要总结

A single arm phase 2 study to study the outcome of dose-escalation with simultaneous integrated boost to intraprostatic lesion and positive lymph nodes. Prostate cancer patients with high risk of lymph node metastasis or oligo positive nodes in true pelvic area can be included. The boost volumes will be outlined by usin PET-CT and MRI data. Our hypothesis is that we will have fewer relapses in this very high risk patient group compared to matched historical controls with acceptable side effects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Histologically confirmed high risk prostate cancer with a risk of lymphatic spread >15% according to the MSKCC nomogram (1) http://nomograms.mskcc.org/Prostate/PreTreatment.aspx
  • Written informed consent
  • > 18 years
  • Fiducial gold markers implanted in the prostate (min 3)

排除标准

  • • Non MR-safe implants or other contraindication to MRI
  • WHO PS>1
  • Previous pelvic irradiation
  • TURP within 6 months
  • IPSS >19
  • Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the pelvis
  • Creatinin clearance < 30ml/min according to http://www.fass.se/LIF/produktfakta/kreatinin.jsp

结局指标

主要结局

PSA progression free survival

时间窗: 36 months

PSA progression defined according to American Society for Therapeutic Radiology and Oncology (ASTRO) Phoenix definition: nadir PSA + 2 ng/mL (on three consecutive measurements with at least one month between each)

次要结局

  • Genitourinary Quality of Life(0 6 12 36 60 months)
  • Gastrointestinal Quality of Life(0 6 12 36 60 months)
  • Sexual Quality of Life(0 6 12 36 60 months)
  • Overall Quality of Life(0 6 12 36 60 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Camilla Thellenberg Karlsson

MD, PhD

Umeå University

研究点 (2)

Loading locations...

相似试验

Dose Escalation With SIB to Intraprostatic/Lymphatic... | 临床试验